title: Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
abstract: Simultaneous inhibition of the acetyl-CoA carboxylase (ACC) isozymes ACC1 and ACC2 results in concomitant inhibition of fatty acid synthesis and stimulation of fatty acid oxidation and may favorably affect the morbidity and mortality associated with obesity, diabetes, and fatty liver disease. Using structure-based drug design, we have identified a series of potent allosteric protein-protein interaction inhibitors, exemplified by ND-630, that interact within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). Together, these data suggest that ACC inhibition by representatives of this series may be useful in treating a variety of metabolic disorders, including metabolic syndrome, type 2 diabetes mellitus, and fatty liver disease.
authors.affiliation: Nimbus Therapeutics, Cambridge, MA 02141;
authors.forename: Geraldine
authors.initials: G
authors.lastname: Harriman
authors.affiliation: Schrodinger Inc., New York, NY 10036;
authors.forename: Jeremy
authors.initials: J
authors.lastname: Greenwood
authors.affiliation: Schrodinger Inc., New York, NY 10036;
authors.forename: Sathesh
authors.initials: S
authors.lastname: Bhat
authors.affiliation: Pharmaron Beijing Co. Ltd., Beijing 100176, China;
authors.forename: Xinyi
authors.initials: X
authors.lastname: Huang
authors.affiliation: Department of Biological Sciences, Columbia University, New York, NY 10027;
authors.forename: Ruiying
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of Biological Sciences, Columbia University, New York, NY 10027;
authors.forename: Debamita
authors.initials: D
authors.lastname: Paul
authors.affiliation: Department of Biological Sciences, Columbia University, New York, NY 10027;
authors.forename: Liang
authors.initials: L
authors.lastname: Tong
authors.affiliation: Department of Medicine and Physiology, School of Medicine, Endocrinology, Diabetes, and Nutrition, Boston University, Boston, MA 02118.
authors.forename: Asish K
authors.initials: AK
authors.lastname: Saha
authors.affiliation: Nimbus Therapeutics, Cambridge, MA 02141;
authors.forename: William F
authors.initials: WF
authors.lastname: Westlin
authors.affiliation: Nimbus Therapeutics, Cambridge, MA 02141;
authors.forename: Rosana
authors.initials: R
authors.lastname: Kapeller
authors.affiliation: Nimbus Therapeutics, Cambridge, MA 02141; h.james.harwood@gmail.com.
authors.forename: H James
authors.initials: HJ
authors.lastname: Harwood
mesh_terms: D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D050171:Dyslipidemias / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D005234:Fatty Liver / Q000188:drug therapy*; D005260:Female; D056945:Hep G2 Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D062105:Molecular Docking Simulation; D009765:Obesity / Q000188:drug therapy / Q000209:etiology; D055503:Protein Multimerization / Q000187:drug effects; D011744:Pyrimidinones / Q000494:pharmacology*; D017207:Rats, Sprague-Dawley; D011924:Rats, Zucker; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000494:pharmacology*
chemical_list: D004791:Enzyme Inhibitors; C000610197:ND-630; D011744:Pyrimidinones; D013876:Thiophenes; C000588423:ACACA protein, human; C520105:ACACB protein, human; D000103:Acetyl-CoA Carboxylase
keywords: acetyl-CoA carboxylase; enzyme inhibition; fatty liver disease